Short Interest in Anthera Pharmaceuticals, Inc. (OTCMKTS:ANTH) Expands By 6.3%

Anthera Pharmaceuticals, Inc. (OTCMKTS:ANTH) was the recipient of a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 3,400 shares, a growth of 6.3% from the September 15th total of 3,200 shares. Based on an average daily trading volume, of 8,400 shares, the short-interest ratio is presently 0.4 days.

Anthera Pharmaceuticals Price Performance

Anthera Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $0.00.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy.